1) Scope of the Terms
These General Terms and Conditions (GTC) regulate the business relationship between persons who have registered for the beta subscription (these persons are hereinafter called "beta subscribers") of med111 and the provider of med111, Infomed-Verlags-AG (hereinafter called "Infomed") from Wil (SG), Switzerland.
Infomed is a not-for-profit publishing company that has been publishing information that promotes the proper use of drugs in the general medical practice and in healthcare services since 1979. The information provided by Infomed is exclusively motivated by the desire to support sick persons and it is financed entirely through the proceeds from its publications. Med111 complements Infomed's existing range of publications.
Beta subscribers must be natural persons of full legal capacity (minimum age 18 years) or legal entities entered in the commercial register.
By expressly confirming the acceptance of the GTC when subscribing to med111 and by using the service, beta subscribers of med111 agree to these GTC and the data protection provisions
which are also an integral part of the agreement.
The testing and introduction phase of med111 serves the purpose of testing the new functionality with regard to editorial content, technical accuracy and commercial integrity and, if necessary, to improve the service for future paid subscriptions. Participation as a beta subscriber in the testing and introduction phase is free of charge.
2) Period of Validity
The testing and introduction phase is expected to end on September 30, 2018. Infomed reserves the right to extend this phase, which would also extend the validity of these GTC.
Infomed also reserves the right to terminate the testing and introduction phase earlier than stated here, which would shorten the validity of these GTC accordingly.
After the testing and introduction phase has been completed, the beta subscriber's username and password will no longer allow access to the med111 drug leaflet functionality.
3) Scope of Use
The med111 website is a password-protected online information service designed primarily for health professionals who would like to provide their patients or customers with information on medications in an easy-to-understand, plain language format. The information available on med111 is laid out on A4-size pages and can be printed and handed out both on paper and/or electronically.
The beta subscription is intended exclusively for registered users who wish to provide drug leaflets to their patients or customers. The leaflets distributed to the patients and customers must always be the currently available version of the leaflet, i.e. med111 expects its beta subscribers to always download the leaflets from the web server. The distribution of med111 leaflets must always be free of charge.
Any form account sharing in order to access med111 is not permitted. In the event of infringements, Infomed reserves the right to block a user's access at any time without any further obligations on the part of Infomed and to delete the user's account.
Beta subscriptions are intended for a single natural person and are limited by the number of fact sheets that can be created or printed per day and per month. Any form of automated retrieval of information sheets and their distribution in other systems is prohibited.
Infomed reserves the right to control and log the activities of beta subscribers on med111, including access, for the purpose of checking compliance with these conditions. Further details can be found in the data protection regulations
4) Mandatory User Details
Med111 requires the correct name and a valid e-mail address of each individual registering for a beta subscription. An automated creation of multiple accounts is not permitted. Beta subscribers agree to use their access data (in particular their password) in accordance with the contract and not to make it available to third parties without the written consent of Infomed. Beta subscribers are responsible for protecting their access data.
Beta subscribers must immediately update their profile on the pages provided on med111 or inform Infomed of such changes in writing at email@example.com
5) Communication with Beta Subscribers
All correspondence and notifications regarding beta subscriptions are distributed by e-mail.
6) Services of med111
As a rule, the med111 website is available without interruption. Infomed reserves the right to limit and/or temporarily suspend these operating hours for technical reasons and to modify the contents and functionalities of med111 at any time. Ongoing changes and adjustments are to be expected. Infomed reserves the right to restrict the functionalities of med111 at any time and without compensation or to discontinue them in whole or in part.
For beta subscribers who need support with med111, instructions are available online
. If the support pages do not resolve the problem beta subscribers can submit their issue through the online contact form
or send an e-mail to firstname.lastname@example.org
. Infomed will try to resolve the issues as quickly as possible, but the beta subscription does not include explicit support from Infomed.
7) Mandatory Technical Requirements for the Subscriber
To be able to use the full range of functionalities provided by med111, beta subscribers must meet the following technical requirements (which essentially correspond to an office computer):
- Users need an Internet connection
- Users need an up-to-date version of one the following browsers: Chrome, Firefox, Internet Explorer or Safari
- Users need the ability to read PDF files within their browser
- Users need a printer.
A mobile-optimized version of med111 for smartphones and other similar devices is currently not implemented.
8) Obligations of the Subscribers
Beta subscribers agree to hold Infomed harmless from any costs, claims, damages, losses or other claims that may arise from their med111 beta subscription or for any other reason.
Beta subscriptions cannot be terminated. If beta subscribers wish to be removed from the system, they can write an email to email@example.com
so that their account can be deleted.
If a violation of these GTC or the data protection regulations
is suspected, Infomed reserves the right to suspend beta subscribers' med111 access and to temporarily or permanently block said users without prior notification.
Infomed is a publisher specialized in the publication of information on the use of prescription medications in the context of the general medical practice. All contents and in particular the med111 leaflets and their translations have been prepared with due care. However, no responsibility can be taken for the accuracy, completeness and currency of the contents.
Infomed is committed to ensuring high quality content and round-the-clock availability of med111, but temporary restrictions and failures (operational interruptions, troubleshooting, maintenance work, etc.) cannot be ruled out. Access and use of the beta subscription is at your own risk. Any guarantee regarding the med111 service is therefore expressly excluded.
Furthermore, Infomed is not liable for services provided by third parties. This applies to any links to contents and offers of third parties for whose legality, correctness, completeness and availability Infomed assumes no responsibility or liability. Nor is Infomed liable for damages caused by computer viruses and other harmful computer programs such as malware or spyware.
The liability of Infomed (as well as of affiliated companies, employees, representatives and vicarious agents) is in any case limited to intentional or grossly negligent violations of contractual and non-contractual obligations for which Infomed is responsible and for which Infomed has been found guilty. To the extent permitted by law, Infomed's liability is limited to the amount invoiced by Infomed for the purchase of the corresponding chargeable services. The liability of Infomed for consequential damages and lost profit is excluded.
Infomed reserves all copyrights and other protective rights concerning the med111 website including layout, software and its contents. In particular, publishing, modifying, offering, selling, duplicating, distributing, perceptualizing, sending, renting and licensing the editorial and other contents of the provider (texts, tables, images, videos, graphics, programs and other services and media offers) is only permitted within the scope described under 3) Scope of Use. Furthermore, the production, transfer and/or sale of second-hand works is not permitted. It is prohibited to display the provider's websites or their contents in whole or in part using technical tools (e.g. "framing").
The software that Infomed uses to provide this digital service is protected by copyright and it is not permitted to use it contrary to the provisions laid down here. In particular, it is prohibited to copy, rebuild, modify or process the software in any other way.
12) Data Privacy
The data protection provisions are set out in a separate declaration and form an integral part of these GTC.
13) Applicable Law and Place of Jurisdiction
Swiss substantive law is applicable to all legal relationships between Infomed-Verlags-AG and the users of med111. The exclusive place of jurisdiction for disputes arising from these terms and conditions and the integral data protection provisions therein is Wil (SG), Switzerland, where the office of Infomed-Verlags-AG is registered, except in cases of any other mandatory places of jurisdiction.
14) Partial Invalidity
Failure by Infomed to enforce its rights under these Terms and Conditions shall not constitute a waiver by Infomed of any such rights and claims. Should individual provisions contained in these General Terms and Conditions be declared invalid or unenforceable, this shall not prevent the validity of the remaining provisions. The invalid provision shall be replaced by a new provision which corresponds in its economic and legal effect to the invalid provision.
15) Adjustments to these GTC